---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053974"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:41:36.864919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q1 net loss $58.3M; cash $435.7M funds operations into 2027

## Summary
- Cash and marketable securities $435.7M as of Mar 31, 2024, up from $273.2M year-end 2023.
- Net loss $58.3M in Q1 2024 vs $38.6M in Q1 2023; R&D expenses $52.7M (up 46% YoY).
- Enrollment on track in APEX, PEAK (end 2024) and SUMMIT (Q2 2025); topline results expected in 2025.
- Completed oversubscribed private placement yielding $213.4M net proceeds.
- Selected 100 mg once-daily dose for SUMMIT Part 2 based on 51% mean TSS improvement at week 12.

## SEC filing metadata
- accession: 0000950170-24-053974
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/0000950170-24-053974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/cogt-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053974
- JSON: https://secwatch.observer/filing/0000950170-24-053974.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053974.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $58.3 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was $58.3 million
  - Result: reported results
  source text: Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017024053974/0000950170-24-053974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.